Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 963

1.

HIV-1 envelope glycoproteins isolated from Viremic Non-Progressor individuals are fully functional and cytopathic.

Cabrera-Rodríguez R, Hebmann V, Marfil S, Pernas M, Marrero-Hernández S, Cabrera C, Urrea V, Casado C, Olivares I, Márquez-Arce D, Pérez-Yanes S, Estévez-Herrera J, Clotet B, Espert L, López-Galíndez C, Biard-Piechaczyk M, Valenzuela-Fernández A, Blanco J.

Sci Rep. 2019 Apr 3;9(1):5544. doi: 10.1038/s41598-019-42075-3.

2.

Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice.

Santos JR, Curran A, Navarro-Mercadé J, Ampuero MF, Pelaez P, Pérez-Álvarez N, Clotet B, Paredes R, Moltó J.

AIDS Res Hum Retroviruses. 2019 Mar 26. doi: 10.1089/AID.2018.0178. [Epub ahead of print]

PMID:
30909716
3.

Predicting virological response to HIV treatment over time: a tool for settings with different definitions of virological response.

Revell AD, Wang D, Perez-Elias MJ, Wood R, Tempelman H, Clotet B, Reiss P, van Sighem AI, Alvarez-Uria G, Nelson M, Montaner JS, Lane HC, Larder BA.

J Acquir Immune Defic Syndr. 2019 Feb 14. doi: 10.1097/QAI.0000000000001989. [Epub ahead of print]

PMID:
30865186
4.

Approach to amoebic colitis: Epidemiological, clinical and diagnostic considerations in a non-endemic context (Barcelona, 2007-2017).

Roure S, Valerio L, Soldevila L, Salvador F, Fernández-Rivas G, Sulleiro E, Mañosa M, Sopena N, Mate JL, Clotet B.

PLoS One. 2019 Feb 21;14(2):e0212791. doi: 10.1371/journal.pone.0212791. eCollection 2019.

5.

Real World Patient-reported Outcomes in HIV-infected Adults Switching to EVIPLERA®, Because of a Previous Intolerance to cART. PRO-STR Study.

Podzamczer D, Rozas N, Domingo P, Miralles C, den Eynde EV, Romero A, Deig E, Knobel H, Pasquau J, Antela A, Clotet B, Geijo P, de Castro ER, Casado MA, Muñoz A, Casado A, For The Pro-Str Study Group.

Curr HIV Res. 2018;16(6):425-435. doi: 10.2174/1570162X17666190212163518.

PMID:
30760189
6.

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA.

Amele S, Peters L, Sluzhynska M, Yakovlev A, Scherrer A, Domingo P, Gerstoft J, Viard JP, Gisinger M, Flisiak R, Bhaghani S, Ristola M, Leen C, Jablonowska E, Wandeler G, Stellbrink H, Falconer K, D'Arminio Monforte A, Horban A, Rockstroh JK, Lundgren JD, Mocroft A; EuroSIDA study group.

HIV Med. 2019 Apr;20(4):264-273. doi: 10.1111/hiv.12711. Epub 2019 Feb 8.

PMID:
30734998
7.

Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8+ T Cells Limit the Killing of HIV-1 Reactivated Cells.

Ruiz A, Blanch-Lombarte O, Jimenez-Moyano E, Ouchi D, Mothe B, Peña R, Galvez C, Genescà M, Martinez-Picado J, Goulder P, Barnard R, Howell B, Clotet B, Prado JG.

Front Immunol. 2019 Jan 22;9:3162. doi: 10.3389/fimmu.2018.03162. eCollection 2018.

8.

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption.

Rockstroh JK, Asmuth D, Pantaleo G, Clotet B, Podzamczer D, van Lunzen J, Arastéh K, Mitsuyasu R, Peters B, Silvia N, Jolliffe D, Ökvist M, Krogsgaard K, Sommerfelt MA.

PLoS One. 2019 Jan 30;14(1):e0210965. doi: 10.1371/journal.pone.0210965. eCollection 2019.

9.

Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort.

Llibre JM, Montoliu A, Miró JM, Domingo P, Riera M, Tiraboschi J, Curran A, Homar F, Ambrosioni J, Abdulghani N, Force L, Peraire J, Casabona J; PISCIS Cohort group.

HIV Med. 2019 Mar;20(3):237-247. doi: 10.1111/hiv.12710. Epub 2019 Jan 27.

PMID:
30688007
10.

Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection.

Malin JJ, Boesecke C, Schwarze-Zander C, Wasmuth JC, Schlabe S, Trebicka J, Spengler U, Llibre JM, Jou T, Vasylyev M, Clotet B, Rockstroh JK.

HIV Med. 2019 Mar;20(3):230-236. doi: 10.1111/hiv.12705. Epub 2019 Jan 27.

PMID:
30687989
11.

NEU Screen Shows High Accuracy in Detecting Cognitive Impairment in Older Persons Living With HIV.

Prats A, López-Masramon E, Pérez-Álvarez N, Garolera M, Fumaz CR, Ferrer MJ, Clotet B, Muñoz-Moreno JA.

J Assoc Nurses AIDS Care. 2019 Jan-Feb;30(1):35-41. doi: 10.1097/JNC.0000000000000003.

PMID:
30586082
12.

Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies.

Carrillo J, Clotet B, Blanco J.

Front Immunol. 2018 Oct 23;9:2429. doi: 10.3389/fimmu.2018.02429. eCollection 2018. Review.

13.

Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant.

Salgado M, Kwon M, Gálvez C, Badiola J, Nijhuis M, Bandera A, Balsalobre P, Miralles P, Buño I, Martinez-Laperche C, Vilaplana C, Jurado M, Clotet B, Wensing A, Martinez-Picado J, Diez-Martin JL; IciStem Consortium.

Ann Intern Med. 2018 Nov 20;169(10):674-683. doi: 10.7326/M18-0759. Epub 2018 Oct 16.

PMID:
30326031
14.

Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.

Inzaule SC, Hamers RL, Noguera-Julian M, Casadellà M, Parera M, Kityo C, Steegen K, Naniche D, Clotet B, Rinke de Wit TF, Paredes R; PanAfrican Studies to Evaluate Resistance.

Lancet HIV. 2018 Nov;5(11):e638-e646. doi: 10.1016/S2352-3018(18)30177-2. Epub 2018 Sep 30.

PMID:
30282603
15.

Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection.

Guillén Y, Noguera-Julian M, Rivera J, Casadellà M, Zevin AS, Rocafort M, Parera M, Rodríguez C, Arumí M, Carrillo J, Mothe B, Estany C, Coll J, Bravo I, Herrero C, Saz J, Sirera G, Torrella A, Navarro J, Crespo M, Negredo E, Brander C, Blanco J, Calle ML, Klatt NR, Clotet B, Paredes R.

Mucosal Immunol. 2019 Jan;12(1):232-246. doi: 10.1038/s41385-018-0083-7. Epub 2018 Aug 31.

PMID:
30171206
16.

Incidence of cervical high-grade squamous intraepithelial lesions in HIV-1-infected women with no history of cervical pathology: up to 17 years of follow-up.

Videla S, Tarrats A, Ornelas A, Badia R, Castella E, Alcalde C, Chamorro A, Esté JA, Clotet B, Sirera G.

Int J STD AIDS. 2019 Jan;30(1):56-63. doi: 10.1177/0956462418792653. Epub 2018 Aug 31.

PMID:
30170532
17.

Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort.

Pelchen-Matthews A, Ryom L, Borges ÁH, Edwards S, Duvivier C, Stephan C, Sambatakou H, Maciejewska K, Portu JJ, Weber J, Degen O, Calmy A, Reikvam DH, Jevtovic D, Wiese L, Smidt J, Smiatacz T, Hassoun G, Kuznetsova A, Clotet B, Lundgren J, Mocroft A; EuroSIDA study.

AIDS. 2018 Oct 23;32(16):2405-2416. doi: 10.1097/QAD.0000000000001967.

PMID:
30134296
18.

High Prevalence of Sarcopenia in HIV-Infected Individuals.

Echeverría P, Bonjoch A, Puig J, Estany C, Ornelas A, Clotet B, Negredo E.

Biomed Res Int. 2018 Jul 12;2018:5074923. doi: 10.1155/2018/5074923. eCollection 2018.

19.

Effectiveness of physically ablative and pharmacological treatments for anal condyloma in HIV-infected men.

Vela S, Videla S, Ornelas A, Revollo B, Clotet B, Sirera G, Piñol M, García-Cuyás F.

PLoS One. 2018 Aug 1;13(8):e0199033. doi: 10.1371/journal.pone.0199033. eCollection 2018.

20.

Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm.

Vamvaka E, Farré G, Molinos-Albert LM, Evans A, Canela-Xandri A, Twyman RM, Carrillo J, Ordóñez RA, Shattock RJ, O'Keefe BR, Clotet B, Blanco J, Khush GS, Christou P, Capell T.

Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):E7854-E7862. doi: 10.1073/pnas.1806022115. Epub 2018 Jul 30.

Supplemental Content

Loading ...
Support Center